MTCR · Metacrine, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $1.32M | $2.31M | $6.68M | - | $14.07M | $11.37M | $6.36M | - | $7.65M |
| SG&A | $3.84M | $3.41M | $5.48M | - | $4.01M | $3.99M | $1.60M | - | $1.07M |
| Total Operating Expenses | $5.16M | $5.76M | $12.51M | - | $18.08M | $15.36M | $7.96M | - | $8.72M |
| D&A | - | - | $68.0K | - | $100.0K | $100.0K | $68.0K | - | - |
| Operating Income | ($5.16M) | ($5.76M) | ($12.51M) | - | ($18.08M) | ($15.36M) | ($7.96M) | - | ($8.91M) |
| Interest Expense | $550.0K | $511.0K | $414.0K | - | $252.0K | $247.0K | $253.0K | - | $258.0K |
| Income Tax | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.52M) | ($6.26M) | ($12.88M) | - | ($18.33M) | ($9.32M) | ($8.11M) | - | ($8.46M) |
| EPS - Basic | ($0.69) | ($0.59) | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.13) | ($0.59) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.75M | $45.35M | $33.03M | $48.91M | $17.03M | $17.15M | $19.46M | $24.39M | $15.67M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $691.0K | $503.0K | $264.0K | $368.0K | $323.0K | $261.0K | $325.0K | $334.0K | $239.0K |
| Current Assets | $55.04M | $59.14M | $66.74M | $78.74M | $65.58M | $79.65M | $90.71M | $102.02M | $110.90M |
| Total Assets | $55.04M | $59.14M | $66.74M | $79.99M | $67.51M | $81.39M | $92.68M | $104.24M | $60.28M |
| Current Liabilities | $4.53M | $2.65M | $5.47M | $7.76M | $10.36M | $7.49M | $5.24M | $4.03M | $4.39M |
| Long-term Debt | $12.58M | $13.62M | $13.43M | $13.30M | $9.11M | $9.50M | $9.43M | $9.37M | $9.31M |
| Total Liabilities | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $37.06M | $41.48M | $46.45M | $57.35M | $47.12M | $63.26M | ($85.89M) | $89.28M | $98.16M |
| Retained Earnings | ($207.62M) | ($202.09M) | ($195.83M) | ($182.95M) | ($169.43M) | ($151.10M) | ($135.51M) | ($120.75M) | ($83.44M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($13.70M) | - | - | - | ($8.60M) | - | - |
| Investing Cash Flow | - | - | ($2.18M) | - | - | - | $5.67M | - | - |
| Financing Cash Flow | - | - | - | - | - | - | ($9.0K) | - | - |
| CapEx | - | - | - | - | - | - | $73.0K | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($8.68M) | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 1.07 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.0% | -10.6% | -19.3% | - | -27.1% | -11.5% | -8.8% | - | -14.0% |
| Return on equity | -14.9% | -15.1% | -27.7% | - | -38.9% | -14.7% | 9.4% | - | -8.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 12.15 | 22.29 | 12.19 | 10.15 | 6.33 | 10.63 | 17.33 | 25.34 | 25.27 |
| Quick ratio | 12.15 | 22.29 | 12.19 | 10.15 | 6.33 | 10.63 | 17.33 | 25.34 | 25.27 |
| Cash ratio | 11.65 | 17.09 | 6.04 | 6.30 | 1.64 | 2.29 | 3.72 | 6.06 | 3.57 |
| Leverage | |||||||||
| Debt / Equity | 0.34 | 0.33 | 0.29 | 0.23 | 0.19 | 0.15 | -0.11 | 0.10 | 0.09 |
| Debt / Assets | 0.23 | 0.23 | 0.20 | 0.17 | 0.13 | 0.12 | 0.10 | 0.09 | 0.15 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | -9.4x | -11.3x | -30.2x | - | -71.7x | -62.2x | -31.5x | - | -34.5x |
| Equity multiplier | 1.48 | 1.43 | 1.44 | 1.39 | 1.43 | 1.29 | -1.08 | 1.17 | 0.61 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - |
| Efficiency | |||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 71.4% | 62.5% | -57.1% | - | -102.9% | - | - | - | - |
| Net income growth (YoY) | 69.9% | 32.8% | -58.8% | - | -116.5% | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -21.3% | -34.4% | - | -35.8% | -52.0% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Metacrine against the 5 most active filers in the same SIC group.